Ovarian hyperstimulation syndrome (OHSS) is one of the major complications in artificial reproductive technology, especially in high responders. Exogenous human chorionic gonadotropin (hCG) for triggering final oocyte maturation during controlled ovarian stimulation (COS) is primarily responsible for the pathogenesis of early-onset OHSS. Several strategies were offered to prevent OHSS, includin...

BACKGROUND Gonadotropin-releasing hormone agonists (GnRHa) might play a role in preserving ovarian function in lymphoma patients by inhibiting chemotherapy-induced ovarian follicular damage. However, studies of its clinical efficacy have reported conflicting results. METHOD We conducted a meta-analysis to determine the effect of the preservation of ovarian function by administering GnRHa in y...

Gonadotropin-releasing hormone analog (GnRHa) therapy is used in idiopathic central precocious puberty (ICPP) worldwide. It has also been shown that during this therapy, body mass index (BMI) increases slightly as a side effect. We investigated the side effects of GnRHa treatment in ICPP on body composition and insulin resistance (IR). Twenty girls (7.55 +/- 1.02 y) with ICPP were treated with ...

Gonadotrophin-releasing hormone agonists (GnRHa) are routinely used in IVF programmes to prevent an unwanted LH surge and consequent ovulation. Despite its widespread use in IVF, a convincing dose recommendation for GnRHa in IVF does not exist. In our opinion, the lowest possible dose of GnRHa should be used. Thus, we performed a prospective, randomized, double-blind, placebo-controlled study t...

We studied 98 in-vitro fertilization (IVF) patients with a high basal follicle stimulating hormone (FSH; >6.5 IU/l) concentration on day 3 who were treated with a low dose gonadotrophin-releasing hormone agonist (GnRHa) protocol and who had received in the previous 6 months a long protocol with GnRHa in a depot formula. The evaluation was made using the previous IVF cycle of the same patient as...

Regarding adjuvant endocrine therapy for premenopausal patients with endocrine sensitive disease, the AGO recommendations have not changed substantially in 2011. Assessment of the menopausal status is best done by menstruation history and follicle-stimulating hormone (FSH) and estradiol (E2) measurements. Low anti-muellerian hormone (AMH) levels seem to be indicative for reduced ovarian reserve...

The first report of the combined use of pituitary suppression and ovarian hyperstimulation in invitro fertilization (IVF) and embryo transfer programmes was published in 1984 (1). Since then, the advantages of gonadotrophin hormonereleasing hormone analogues (GnRHa) have been well documented; the cancellation rate has been decreased through the prevention of premature luteinizing hormone (LH) s...